Skip to main content

Table 3 Univariate and multivariate Cox regression survival analysis of breast cancer-specific survival (CSS) and time to recurrence (TTR) as a function of Nuc-Stat5a in breast cancer patients treated with antiestrogen monotherapy (Materials V and VI)

From: Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes

Material V CSS (n= 73)

 

Multivariate adjusted (Cox)

Univariate unadjusted (Cox)

Variable

n

Hazard ratio (95% CI)

Pvalue

Hazard ratio (95% CI)

Pvalue

Grade

1

17

1

-

1

-

 

2

43

3.42 (0.42 to 27.87)

0.251

3.74 (0.46 to 30.52)

0.218

 

3

13

2.60 (0.23 to 29.30)

0.438

3.32 (0.30 to 36.66)

0.327

Size

< 2 cm

40

1

-

1

-

 

≥2 to ≥5 cm

33

4.29 (0.86 to 21.38)

0.075

5.79 (1.23 to 27.26)

0.026

Stat5a

Low (0)

9

4.19 (1.13 to 15.48)

0.032

6.73 (1.88 to 24.05)

0.003

 

High (> 0)

64

1

-

1

-

Global test for PH assumption: χ2(3) = 1.67; P = 0.64.

Material V TTR ( n = 73)

 

Multivariate adjusted (Cox)

Univariate unadjusted (Cox)

Variable

n

Hazard ratio (95% CI)

P value

Hazard ratio (95% CI)

P value

Grade

1

17

1

 

1

 
 

2

43

1.20 (0.30 to 4.81)

0.794

1.27 (0.32 to 5.04)

0.729

 

3

13

1.59 (0.31 to 8.22)

0.581

1.87 (0.37 to 9.39)

0.448

Size

< 2 cm

40

1

 

1

 
 

≥2 to ≥5 cm

33

1.63 (0.49 to 5.43)

0.429

2.24 (0.73 to 6.86)

0.158

Stat5a

Low (0)

9

4.27 (1.20 to 15.19)

0.025

5.08 (1.52 to 17.01)

0.008

 

High (> 0)

64

1

 

1

 

Global test for PH assumption: χ2(3) = 1.47; P = 0.69.

Material VI CSS ( n = 55)

 

Multivariate adjusted (Cox)

Univariate unadjusted (Cox)

Variable

n

Hazard ratio (95% CI)

P value

Hazard ratio (95% CI)

P value

Grade

1

8

1

-

1

-

 

2

28

3.48 (0.91 to 13.31)

0.068

1.11 (0.36 to 3.41)

0.855

 

3

19

2.83 (0.65 to 12.28)

0.164

2.25 (0.73 to 6.91)

0.158

Size

< 2 cm

24

1

-

1

-

 

2 to ≥5 cm

26

3.51 (1.26 to 9.74)

0.016

4.22 (1.76 to 10.13)

0.001

 

≥5 cm

5

8.54 (1.92 to 37.94)

0.005

6.94 (2.01 to 24.00)

0.002

LN status

Neg

29

1

-

1

-

 

Pos

26

4.72 (1.90 to 11.74)

< 0.001

4.30 (1.98 to 9.33)

< 0.001

ER/PR status

Neg

8

1

-

1

-

 

Pos

47

0.73 (0.22 to 2.38)

0.597

0.37 (0.16 to 0.86)

0.021

Her2 status

Neg

48

1

-

1

-

 

Pos

7

2.87 (0.92 to 8.96)

0.070

3.07 (1.23 to 7.63)

0.016

Stat5a

Low (< 1,454)

16

4.95 (1.87 to 13.06)

0.001

2.75 (1.33 to 5.69)

0.006

 

High (≥1,454)

39

1

-

1

-

Global test for PH assumption: χ2(6) = 3.19; P = 0.78.

Material VI TTR ( n = 55)

 

Multivariate adjusted (Cox)

Univariate unadjusted (Cox)

Variable

n

Hazard ratio (95% CI)

P value

Hazard ratio (95% CI)

P value

Grade

1

8

1

-

1

-

 

2

28

1.17 (0.37 to 3.72)

0.794

0.87 (0.31 to 2.41)

0.783

 

3

19

1.24 (0.33 to 4.68)

0.746

1.98 (0.71 to 5.55)

0.191

Size

< 2 cm

24

1

-

1

-

 

2 to ≥5 cm

26

3.38 (1.30 to 8.80)

0.013

3.75 (1.67 to 8.43)

0.001

 

≥5 cm

5

8.17 (2.26 to 29.50)

0.001

6.91 (2.27 to 21.06)

< 0.001

LN status

Neg

29

1

-

1

-

 

Pos

26

3.46 (1.57 to 7.64)

0.002

3.42 (1.67 to 7.01)

< 0.001

ER/PR status

Neg

8

1

-

1

-

 

Pos

47

0.51 (0.17 to 1.48)

0.214

0.30 (0.13 to 0.68)

0.004

Her2 status

Neg

48

1

-

1

-

 

Pos

7

3.35 (1.13 to 9.93)

0.029

3.06 (1.24 to 7.56)

0.015

Stat5a

Low (< 1,454)

16

2.14 (0.89 to 5.12)

0.087

2.15 (1.06 to 4.35)

0.033

 

High (≥1,454)

39

1

-

1

-

  1. Global test for PH assumption: χ2(6) = 4.67; P = 0.59. CI, confidence interval; ER/PR status, estrogen or progesterone receptor positive; HR, hazard ratio; LN status, lymph node status.